North Dakota State Investment Board bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,065 shares of the life sciences company’s stock, valued at approximately $2,238,000.
Several other institutional investors have also recently added to or reduced their stakes in ILMN. Capital World Investors lifted its stake in Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Nordea Investment Management AB lifted its stake in Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Illumina during the fourth quarter worth approximately $73,532,000. State Street Corp lifted its stake in Illumina by 6.8% during the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the last quarter. Finally, Duquesne Family Office LLC purchased a new stake in Illumina during the second quarter worth approximately $28,682,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Analyst Ratings Changes
Several research firms recently weighed in on ILMN. Royal Bank Of Canada began coverage on Illumina in a research note on Thursday. They set an “outperform” rating and a $170.00 target price for the company. Piper Sandler reduced their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Robert W. Baird set a $137.00 price objective on Illumina in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Canaccord Genuity Group reduced their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus target price of $137.75.
Illumina Price Performance
Shares of NASDAQ ILMN opened at $141.51 on Tuesday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a twelve month low of $78.55 and a twelve month high of $155.53. The stock has a 50 day moving average of $128.84 and a two-hundred day moving average of $130.03. The stock has a market cap of $21.41 billion, a P/E ratio of 25.73, a P/E/G ratio of 2.36 and a beta of 1.42.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the business earned $0.97 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current year.
Insider Activity
In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 332,530 shares of company stock valued at $48,303,655. Company insiders own 2.90% of the company’s stock.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
